Germany Glp-1 Receptor Agonist Market Size & Outlook
Germany glp-1 receptor agonist market, 2018-2030 (US$M)
Related Markets
Germany glp-1 receptor agonist market highlights
- The Germany glp-1 receptor agonist market generated a revenue of USD 737.0 million in 2023 and is expected to reach USD 2,969.1 million by 2030.
- The Germany market is expected to grow at a CAGR of 22% from 2024 to 2030.
- In terms of segment, ozempic (semaglutide) was the largest revenue generating product in 2023.
- Other Products is the most lucrative product segment registering the fastest growth during the forecast period.
Glp-1 receptor agonist market data book summary
| Market revenue in 2023 | USD 737.0 million |
| Market revenue in 2030 | USD 2,969.1 million |
| Growth rate | 22% (CAGR from 2023 to 2030) |
| Largest segment | Ozempic (semaglutide) |
| Fastest growing segment | Other Products |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Ozempic (semaglutide), Trulicity, Rybelsus (oral semaglutide), Saxenda, Victoza (liraglutide), Other Products |
Other key industry trends
- In terms of revenue, Germany accounted for 2.0% of the global glp-1 receptor agonist market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany glp-1 receptor agonist market is projected to lead the regional market in terms of revenue in 2030.
- Norway is the fastest growing regional market in Europe and is projected to reach USD 1,225.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
GLP-1 Receptor Agonist Market Scope
GLP-1 Receptor Agonist Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Germany glp-1 receptor agonist market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glp-1 receptor agonist market will help companies and investors design strategic landscapes.
Ozempic (semaglutide) was the largest segment with a revenue share of 48.05% in 2023. Horizon Databook has segmented the Germany glp-1 receptor agonist market based on ozempic (semaglutide), trulicity, rybelsus (oral semaglutide), saxenda, victoza (liraglutide), other products covering the revenue growth of each sub-segment from 2018 to 2030.
Germany has one of the strongest healthcare systems in Europe, which covers 90% of the population under mandatory health insurance. This allows easy access to treatments, facilitating the adoption of GLP-1 agonist drugs with an advanced infrastructure.
The presence of key market players in Germany, an increasing focus on geographic expansion, and the launch of new products are among the factors driving the GLP-1 receptor agonist market in Germany. The presence of research institutions & leading drug manufacturers is also propelling the GLP-1 receptor agonist market in the country.
In addition, in Germany, more than half of the adult population is overweight and is prone to type 2 diabetes. This leads to a higher adoption of GLP-1 agonist drugs, which is attributed to the effectiveness and comparable manageable side effects associated with the formulations.
Reasons to subscribe to Germany glp-1 receptor agonist market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Germany glp-1 receptor agonist market databook
-
Our clientele includes a mix of glp-1 receptor agonist market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany glp-1 receptor agonist market , including forecasts for subscribers. This country databook contains high-level insights into Germany glp-1 receptor agonist market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Germany glp-1 receptor agonist market size, by product, 2018-2030 (US$M)
Germany GLP-1 Receptor Agonist Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
